Hospital Universitario De Salamanca
Hospital Universitario De Salamanca is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethasone (KRd) with/without daratumumab, 18 cycles, followed by consolidation and maintenance with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for older adult patients between 65 and 80 years old, in good general health with newly-diagnosed multiple myeloma
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients previously exposed to three-drug classes
Sponsor Pethema Fundacion
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM)
Sponsor Fundacion Pethema
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Sponsor Fundacion Geltamo
- Start (EU)
- Latest update
- Estimated end
A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy, followed by high-dose therapy with melphalan and autologous peripheral blood stem cell transplantation, consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients ≤ 70 years old with smoldering multiple myeloma (SMM) with high risk of progression to symptomatic myeloma
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
LATE-R TRIAL: A PHASE II, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH LATE RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor Fundacion Geltamo
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide.
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Hospital Universitario De Salamanca?
The 2026-10-09 snapshot links Hospital Universitario De Salamanca to 8 distinct CTIS trials. Recorded services include Laboratory services, Routine clinical pathology testing, Unidad de Inmunopatología/Biología Molecular/Citogenética.. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Hospital Universitario De Salamanca?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Hospital Universitario De Salamanca conducted?
The linked trials record locations in 10 countries, including Spain, Greece, Austria, Belgium, Czechia. These are trial locations, not confirmed office locations or countries where Hospital Universitario De Salamanca delivered services.
What can this page tell me about Hospital Universitario De Salamanca's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Hospital Universitario De Salamanca. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Hospital Universitario De Salamanca